Table 4 Adverse Events
From: Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
Total N(%) | Grade | |||
|---|---|---|---|---|
1 | 2 | 3–4 | ||
Apatinib alonea | 45 (100%) | |||
Fatigue | 8(17.8%) | 5 | 2 | 1 |
Hypertension | 35(77.8%) | 27 | 3 | 5 |
Proteinuria | 4(8.9%) | 3 | 1 | |
Hand-foot syndrome | 12(26.7%) | 10 | 2 | |
Diarrhea | 9(20%) | 5 | 3 | 1 |
Weight loss | 19(42.2%) | 17 | 2 | |
Hair hypopigmentation | 25(55.6%) | 20 | 5 | |
Anorexia | 17(37.8%) | 10 | 4 | 3 |
Rash or desquamation | 26(57.8%) | 15 | 9 | 2 |
Mucositis | 2(4.4%) | 2 | ||
Pneumothorax | 9(20%) | 3 | 6 | |
Wound-healing problems | 6(13.3%) | 1 | 5 | |
Elevated Aminotransferase or bilirubin | 3(6.7%) | 2 | 1 | |
Thrombocytopenia | 7(15.6%) | 5 | 1 | 1 |
Seizure-like attack | 1(2.3%) | 1 | ||
Pancreatitis | 1(2.2%) | 1 | ||
Anemia | 2(4.4%) | 2 | ||
Cranial neuritis | 1(2.3%) | 1 | ||
Apatinib + everolimusb | 7 (100%) | |||
Mucositis | 7(100%) | 2 | 4 | 1 |
Hypertension | 4(57.1%) | 2 | 2 | |
Rash or desquamation | 5(71.4%) | 2 | 3 | |
Gastrointestinal uncomfort | 1(14.3%) | 1 | ||
Apatinib + GTc | 5 (100%) | |||
Hypertension | 1(20%) | 1 | ||
Rash or desquamation | 2(40%) | 2 | ||
Wound-healing problems | 1(20%) | 1 | ||
Thrombocytopenia | 2(40%) | 1 | 1 | |